MEIRAGTX HLDGSDL-0000388
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 … Read more
MEIRAGTX HLDGSDL-0000388 (328) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MEIRAGTX HLDGSDL-0000388 (328) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MEIRAGTX HLDGSDL-0000388 - Net Assets Trend (None–None)
This chart illustrates how MEIRAGTX HLDGSDL-0000388's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MEIRAGTX HLDGSDL-0000388 (None–None)
The table below shows the annual net assets of MEIRAGTX HLDGSDL-0000388 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MEIRAGTX HLDGSDL-0000388's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MEIRAGTX HLDGSDL-0000388 Competitors by Market Cap
The table below lists competitors of MEIRAGTX HLDGSDL-0000388 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jdd Tech New Mat Co Ltd
SHE:301538
|
$224.42 Million |
|
OVH Groupe S.A
PINK:OVHFF
|
$224.42 Million |
|
Reysas Tasimacilik ve Lojistik Ticaret A.S
PINK:RYSKF
|
$224.45 Million |
|
Borussia Dortmund GmbH & Co KGaA
XETRA:BVB
|
$224.49 Million |
|
Live Oak Acquisition Corp. V Units
NASDAQ:LOKVU
|
$224.25 Million |
|
Fujian Oriental Silver Star Investment Co Ltd
SHG:600753
|
$224.12 Million |
|
Centum Electronics Limited
NSE:CENTUM
|
$224.10 Million |
|
NEXT FIFTEEN LS-025
F:8LS
|
$224.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MEIRAGTX HLDGSDL-0000388's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MEIRAGTX HLDGSDL-0000388's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MEIRAGTX HLDGSDL-0000388 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MEIRAGTX HLDGSDL-0000388's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MEIRAGTX HLDGSDL-0000388 (328) | €- | N/A | N/A | $224.40 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |